StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Study Fails to Show Alzheimer's Effectiveness, Says FDA Panel
November 6, 2020 3:19 PM
(Updated - November 6, 2020 4:06 PM EST)Biogen (NASDAQ: BIIB) Study Fails to Show Alzheimer's Effectiveness, Says FDA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Trader Talk
Next Articles
Biogen (BIIB) Confirms Negative FDA Advisory Committee Votes on Aducanumab in Alzheimer's Disease
November 9, 2020 6:41 AM
Cowen Downgrades Biogen (BIIB) to Market Perform
November 9, 2020 6:18 AM
Biotech ETF (IBB) Lower After Biogen (BIIB) FDA Panel Negative Vote on Question 1
November 6, 2020 3:23 PM
